Wesbanco Bank Inc. Reduces Position in Bristol Myers Squibb Company $BMY

Wesbanco Bank Inc. trimmed its stake in Bristol Myers Squibb Company (NYSE:BMY) by 5.5% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 245,082 shares of the biopharmaceutical company’s stock after selling 14,341 shares during the period. Wesbanco Bank Inc.’s holdings in Bristol Myers Squibb were worth $11,053,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of the stock. Gateway Investment Advisers LLC lifted its holdings in Bristol Myers Squibb by 10.0% during the third quarter. Gateway Investment Advisers LLC now owns 113,457 shares of the biopharmaceutical company’s stock valued at $5,117,000 after purchasing an additional 10,284 shares in the last quarter. CWA Asset Management Group LLC raised its position in shares of Bristol Myers Squibb by 25.9% during the 3rd quarter. CWA Asset Management Group LLC now owns 150,359 shares of the biopharmaceutical company’s stock valued at $6,781,000 after purchasing an additional 30,909 shares during the period. Commonwealth Retirement Investments LLC lifted its stake in shares of Bristol Myers Squibb by 24.6% during the 2nd quarter. Commonwealth Retirement Investments LLC now owns 59,183 shares of the biopharmaceutical company’s stock valued at $2,740,000 after buying an additional 11,690 shares in the last quarter. Railway Pension Investments Ltd boosted its holdings in Bristol Myers Squibb by 3.7% in the 3rd quarter. Railway Pension Investments Ltd now owns 1,139,600 shares of the biopharmaceutical company’s stock worth $51,396,000 after buying an additional 40,300 shares during the period. Finally, Stephens Inc. AR raised its stake in Bristol Myers Squibb by 13.5% during the 3rd quarter. Stephens Inc. AR now owns 273,343 shares of the biopharmaceutical company’s stock valued at $12,328,000 after purchasing an additional 32,476 shares during the period. Institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Stock Down 2.0%

Shares of NYSE:BMY opened at $60.75 on Tuesday. The company has a debt-to-equity ratio of 2.39, a current ratio of 1.27 and a quick ratio of 1.17. The business has a 50 day simple moving average of $54.57 and a two-hundred day simple moving average of $49.12. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $63.33. The firm has a market capitalization of $123.67 billion, a PE ratio of 17.61, a price-to-earnings-growth ratio of 0.19 and a beta of 0.29.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 EPS for the quarter, missing the consensus estimate of $1.65 by ($0.39). Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 70.30%. The business had revenue of $12.50 billion during the quarter, compared to the consensus estimate of $12.24 billion. During the same period last year, the company earned $1.67 EPS. The business’s revenue was up 1.3% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, equities analysts predict that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, February 2nd. Shareholders of record on Friday, January 2nd were given a $0.63 dividend. This is a positive change from Bristol Myers Squibb’s previous quarterly dividend of $0.62. The ex-dividend date of this dividend was Friday, January 2nd. This represents a $2.52 annualized dividend and a yield of 4.1%. Bristol Myers Squibb’s dividend payout ratio is presently 73.04%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, November 3rd. Piper Sandler reaffirmed an “overweight” rating and set a $66.00 target price (up from $62.00) on shares of Bristol Myers Squibb in a research note on Wednesday, January 28th. Leerink Partners boosted their price target on shares of Bristol Myers Squibb from $54.00 to $60.00 and gave the stock an “outperform” rating in a research note on Tuesday, January 13th. HSBC restated a “hold” rating and set a $53.00 price objective on shares of Bristol Myers Squibb in a research report on Wednesday, December 10th. Finally, The Goldman Sachs Group reiterated a “neutral” rating and issued a $57.00 target price (up from $51.00) on shares of Bristol Myers Squibb in a research report on Tuesday, December 2nd. Eight analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $59.20.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.